Bone Loss in Men on Androgen Blockade as Adjuvant Therapy for Prostate Cancer
NCT ID: NCT00199537
Last Updated: 2008-07-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
25 participants
OBSERVATIONAL
2005-02-28
2008-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Osteoporosis Among Men Treated With Androgen Deprivation for Prostate Cancer
NCT00957606
Healthy Bones Study
NCT01973673
Strategies to Improve Bone Health in Men on ADT
NCT02043236
Study to Determine the Prevalence of Osteoporosis in Patients With Advanced Prostate Cancer Treated With Hormonal Manipulation
NCT00124410
Bone Health Observational Study
NCT00632905
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age of 40 years or greater
* Diagnosis of advanced prostate cancer (ie: prostate-specific antigen \[PSA\] less than 25 ug/L and undergoing continued treatment with leuteinizing hormone-releasing hormone \[LHRH\] therapy)
* Willing and able to consent
Exclusion Criteria
* Medications affecting bone turnover (bisphosphonate, steroids, anticonvulsant)
* Renal failure (serum creatinine \> 200 umol/L)
* Co-morbidity factors affecting bone density (ie: Paget's, rheumatoid arthritis)
* Factors affecting ability to perform the bone density tests using femoral head measurements (ie: bilateral hip arthroplasty)
* Cancer other than skin, except when, in the investigators' opinion, it is determined to be appropriate and not adversely affect the outcome of the trial
* Gastrointestinal (GI) pathology (eg. malabsorption syndrome)
* Parathyroid disease
40 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Lawson Health Research Institute Internal Review Fund
UNKNOWN
University of Western Ontario, Canada
OTHER
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Lawson Health Research Institute
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hassan Razvi, MD, FRCSC
Role: PRINCIPAL_INVESTIGATOR
Urology, St. Joseph's Hospital, University of Western Ontario
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Urology Clinic & Prostate Centre, St. Joseph's Hospital, St. Joseph's Health Care London
London, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Lawson IRF-071-04
Identifier Type: -
Identifier Source: secondary_id
UWO ADF SG06-02
Identifier Type: -
Identifier Source: secondary_id
R-05-055
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.